1-8 of 8
Orly Eizenberg
Close
Sort by
Journal Articles

The High Affinity CXCR4 Inhibitor, BL-8040, Impairs the Infiltration, Migration, Viability, and Differentiation of Regulatory T Cells

Michal Abraham, Inbal Mishalian, Abi Vainstein, Liron Shemesh-Darvish, Ella Sorani, Orly Eizenberg, Amnon Peled
Journal: Blood
Blood (2021) 138 (Supplement 1): 2804.
https://doi.org/10.1182/blood-2021-147142
Published: 2021
Journal Articles

The CXCR4 Antagonist BL-8040 Induces a Robust Mobilization of CD34+CD38−CD45RA−CD90+ CD49f+ HSCs with Long-Term and Secondary Myeloid and Lymphoid Repopulating Activity

Michal Abraham, PhD, Galia Oberkovitz, PhD, Baruch Bulvik, Klein Shiri, Hanna Wald, Orly Eizenberg, Katia Beider, Arnon Nagler, MD, Abi Vainstein, MD, Eyal Benami, Rotem Golan, Eithan Galun, Yoseph Caraco, Reuven Or, MD, Amnon Peled
Journal: Blood
Blood (2017) 130 (Supplement 1): 660.
https://doi.org/10.1182/blood.V130.Suppl_1.660.660
Published: 2017
Journal Articles

The High Affinity CXCR4 Inhibitor, BL-8040, Induces Apoptosis of AML Blasts and Their Terminal Differentiation By Blocking AKT/ERK Survival Signals and Downregulating BCL-2, MCL-1 and Cyclin-D1 through Regulation of Mir-15a/16-1 Expression

Michal Abraham, PhD, Shiri Klein, Baruch Bulvik, Hanna Wald, Dvora Holam, Lola Weiss, Katia Beider, PhD, Orly Eizenberg, Ori Wald, MD PhD, Abraham Avigdor, MD, Ohad Benjamini, MD, Eithan Galun, MD, Arnon Nagler, Yaron Pereg, PhD, Amnon Peled, PhD
Journal: Blood
Blood (2016) 128 (22): 767.
https://doi.org/10.1182/blood.V128.22.767.767
Published: 2016
Journal Articles

The CXCR4 Antagonist BL-8040 Efficiently Induces Apoptosis and Inhibits The Survival Of AML Cells

Sigal Tavor, MD, Ido Weiss, Katia Beider, Ph.D., Hanna Wald, Orly Eizenberg, Yaron Pereg, Leah Klapper, Arnon Nagler, MD, MSc, Amnon Peled, Michal Abraham, PhD
Journal: Blood
Blood (2013) 122 (21): 3939.
https://doi.org/10.1182/blood.V122.21.3939.3939
Published: 2013
Journal Articles

Combination of Imatinib with CXCR4 Antagonist BKT140 Overcomes the Protective Effect of Stroma and Targets CML in Vitro and in Vivo

Katia Beider, Merav Darash-Yahana, Boaz Pal, Orly Blaier, Maya Koren-Michowitz, Michal Abraham, Hanna Wald, Orly Eizenberg, Amnon Peled, Arnon Nagler, MD
Journal: Blood
Blood (2012) 120 (21): 3735.
https://doi.org/10.1182/blood.V120.21.3735.3735
Published: 2012
Journal Articles

CXCR4 Antagonist BKT140 Synergizes with Rituximab, Targeting Non Hodgkin Lymphoma (NHL) In Vitro and In Vivo in a Xenograft Model with Bone Marrow Involvement

Katia Beider, Elena Ribakovsky, Michal Abraham, Hanna Wald, Orly Eizenberg, Abraham Avigdor, MD, Amnon Peled, PhD, Arnon Nagler
Journal: Blood
Blood (2011) 118 (21): 952.
https://doi.org/10.1182/blood.V118.21.952.952
Published: 2011
Journal Articles

BKT140 Is a Novel CXCR4 Antagonist with Stem Cell Mobilization and Antimyeloma Effects: An Open-Label First Human Trial In Patients with Multiple Myeloma Undergoing Stem Cell Mobilization for Autologous Transplantation

Arnon Nagler, M.D., Avichai Shimoni, Irit Avivi, Jacob M. Rowe, Katia Beider, Izhar Hardan, Michal Abraham, Hanna Wald, Eithan Galun, Howard Laurence Shaw, Orly Eizenberg, Amnon Peled
Journal: Blood
Blood (2010) 116 (21): 2260.
https://doi.org/10.1182/blood.V116.21.2260.2260
Published: 2010
Journal Articles

Anti-Leukemia and Multiple Myeloma Selective Activity of CXCR4 Antagonist 4F-Benzoyl-TN14003 Involves Apoptotic Death Pathway.

Katia Beider, Michal Begin, Michal Abraham, Hanna Wald, Ido Weiss, Ori Wald, Eli Pikarsky, Evelyne Zeira, Orly Eizenberg, Eithan Galun, Arnon Nagler, Amnon Peled
Journal: Blood
Blood (2009) 114 (22): 3857.
https://doi.org/10.1182/blood.V114.22.3857.3857
Published: 2009